REMEDY raises Series A led by L Catterton to modernize dermatologist-developed skincare
What's the deal? REMEDYDealroom has a profile for this one. Try Dealroom →, the skincare brand founded by board-certified dermatologist Dr. Muneeb Shah, has closed a Series A round led by L CattertonDealroom has a profile for this one. Try Dealroom →, the global consumer-focused investment firm. Norwest, which led REMEDY's seed round, and new investor Sonoma Brands CapitalDealroom has a profile for this one. Try Dealroom → also participated.
The funds will go toward clinical research, product development, team expansion, and inventory to meet growing demand across its direct-to-consumer site, Amazon, and Target.
Why now? REMEDY has grown rapidly since launching in March 2024, building traction across online channels including TikTok Shop. It landed a nationwide Target rollout in December 2025, which the company calls a breakout success.
"REMEDY was created to modernize dermatologist-developed skincare," said Dr. Shah, the company's founder and chief executive officer. "Each formula starts with a real patient need. We then innovate with the latest ingredient technologies to create clinically tested, high-efficacy formulas."
The brand positions itself as clinically grounded but accessibly priced — a sweet spot that L Catterton believes will "define the next generation of dermocosmetics," according to partner Tehmina Haider.
What could go wrong? The skincare market is brutally crowded. Dermatologist-backed brands are multiplying, and consumer attention on social media is fickle. REMEDY's growth has leaned heavily on Dr. Shah's personal platform as a skin-care educator — a strength that also concentrates risk around a single founder's public profile.
Scaling in mass retail brings its own challenges: margin pressure, inventory management, and competition for shelf space against deep-pocketed incumbents.
The signal: L Catterton, the world's largest consumer-focused investment fund, backing a brand barely two years old underscores how quickly creator-led beauty companies can reach institutional-grade scale. The round also highlights sustained investor conviction in the "clinical but accessible" pricing tier — a segment where digitally native challengers are increasingly taking share from legacy dermocosmetics incumbents entrenched in prestige retail.
Read more: BusinessWire
